Wedbush Forecasts Reduced Earnings for Oruka Therapeutics

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Analysts at Wedbush reduced their Q2 2025 earnings estimates for shares of Oruka Therapeutics in a research report issued to clients and investors on Wednesday, May 14th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.46) per share for the quarter, down from their previous estimate of ($0.43). Wedbush currently has a “Outperform” rating and a $40.00 target price on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($3.41) per share. Wedbush also issued estimates for Oruka Therapeutics’ Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.82) EPS, Q1 2026 earnings at ($0.48) EPS, Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.53) EPS, Q4 2026 earnings at ($0.53) EPS, FY2026 earnings at ($2.05) EPS, FY2027 earnings at ($2.52) EPS and FY2028 earnings at ($3.34) EPS.

Other equities research analysts also recently issued reports about the stock. Wolfe Research assumed coverage on shares of Oruka Therapeutics in a research note on Tuesday, February 4th. They set an “outperform” rating and a $20.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $45.00 price target on shares of Oruka Therapeutics in a research note on Friday, February 7th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $39.86.

Oruka Therapeutics Price Performance

ORKA opened at $10.06 on Monday. The company has a market cap of $376.66 million, a price-to-earnings ratio of -1.61 and a beta of 0.25. The firm has a 50 day simple moving average of $9.86 and a 200 day simple moving average of $14.68. Oruka Therapeutics has a fifty-two week low of $5.49 and a fifty-two week high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.17.

Hedge Funds Weigh In On Oruka Therapeutics

A number of large investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. acquired a new position in Oruka Therapeutics during the 1st quarter worth approximately $2,505,000. ADAR1 Capital Management LLC bought a new stake in shares of Oruka Therapeutics during the 1st quarter worth approximately $1,362,000. Braidwell LP raised its stake in shares of Oruka Therapeutics by 37.0% during the 1st quarter. Braidwell LP now owns 1,572,426 shares of the company’s stock worth $16,133,000 after purchasing an additional 424,750 shares in the last quarter. OMERS ADMINISTRATION Corp raised its stake in shares of Oruka Therapeutics by 126.8% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 44,900 shares of the company’s stock worth $461,000 after purchasing an additional 25,100 shares in the last quarter. Finally, Affinity Asset Advisors LLC raised its stake in shares of Oruka Therapeutics by 47.9% during the 1st quarter. Affinity Asset Advisors LLC now owns 545,362 shares of the company’s stock worth $5,595,000 after purchasing an additional 176,664 shares in the last quarter. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.